Renal dysfunction in patients with cirrhosis: Where do we stand?

doi:10.4292/wjgpt.v5.i3.156

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4879)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-7) series.

Item

Count

PDF

654

WORD

285

HTML

2691

Tables (1-7)

265

Sum=3895

Aug 6, 2014 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Pharmacol Ther. Aug 6, 2014; 5(3): 156-168
Published online Aug 6, 2014. doi: 10.4292/wjgpt.v5.i3.156

Table 6 Scheme for terlipressin and albumin administration[5,97]

Terlipressin is given as an intravenous bolus 1 to 2 mg every four to six hours

Albumin is given for two days as an intravenous bolus 1 g/kg per day (100 g maximum) followed by 25 to 50 g /d until terlipressin therapy is discontinued

Citation: Pipili C, Cholongitas E. Renal dysfunction in patients with cirrhosis: Where do we stand? World J Gastrointest Pharmacol Ther 2014; 5(3): 156-168
URL: https://www.wjgnet.com/2150-5349/full/v5/i3/156.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v5.i3.156